secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001420720-23-000072
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio amends credit agreement: maturity extended to March 29, 2024, rate cut to 4.5%
--------------------------------------------------------------------------------

- Maturity extended from Dec 31, 2023 to earlier of March 29, 2024 or acceleration of term loan.
- Interest rate reduced from 5.25% to 4.5%; payment-in-kind increased from 3% to 4.5%.
- Borrower must maintain minimum $900K reserve; best efforts to sell cGMP manufacturing facility before maturity.
- Woodforest fee increased by $10,000 to $155,000, payable at sale closing or maturity date.
- Amendment provides additional flexibility to complete divestiture of CDMO business and advance AI immunotherapy platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072023000072/0001420720-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072023000072/ibio-20231222x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer